![]() ![]() Massachusetts-based Moderna develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, and cardiovascular diseases. Additionally, it plans to boost its presence to include 10 more countries in Europe and the Asia Pacific region this year. These include Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, the U.K. The company has a commercial presence in 11 nations across the world. The CEO of Moderna, Stéphane Bancel, said, “A presence in Latin America is a key part of our global commercial strategy.” The agreement covers 18 Latin American countries, including Brazil, Mexico, Colombia, and Argentina. ( NASDAQ: MRNA) has signed a distribution service agreement with Uruguay-based pharmaceutical firm Adium Pharma for the sale of its COVID-19 vaccine, Spikevax, in Latin America. team comprised partner Rodrigo López Márquez and associate Alvaro Alán Perez Caballero.įinally, Brigard & Urrutia’s team integrated partner César Felipe Rodríguez Parra and associates Juan Eduardo Gómez Londoño and Sebastián Ortegón González.Biotechnology company Moderna, Inc. Guyer & Regules team was made up of partner Diego Baldomir, together with associates Javier Napoleone and Micaela Urchitano Pastorini.Ĭonyers Dill & Pearman was supported by partner Robert Briant. Milbank LLP team was led by partner Carlos Albarracin, assisted by associates Gonzalo Guitart and María Velasco. Reyes & Reyes Abogados was represented by partner José Luis Reyes Villamizar. Harney Westwood & Riegels LP’s team consisted of partner Joshua Mangeot and associate Edward Lacey.Ĭaraza y Morayta Abogados participated through partner Fernando Morayta. MCRM’s team was composed by partner Mercedes Rodriguez Giavarini (pictured left) and associate Juan Vignolo (pictured right).īergstein Abogados’ team included partners Jonas Bergstein and Leonardo Melos, along with associate Santiago Di Bello. in Mexico, and Brigard & Urrutia in Colombia.Īdium is a pharmaceutical company founded in 1975 with headquarters in Uruguay and operating in 18 countries in Latin America, dedicated to the development, production and commercialisation of pharmaceutical products, providing access to physicians and patients in Latin America to innovative and quality treatments with a commercial portfolio that includes own brand generics and innovative pharmaceutical products under license in the areas of oncology, rheumatology, pain, urology, women’s health, neurology, cardiology and gastroenterology. In addition, Banco Itaú and the other Lenders were advised by Milbank LLP in Argentina, Guyer & Regules on legal matters in Uruguay, Conyers Dill & Pearman in the British Virgin Islands, Kuri Breña, Sánchez Ugarte y Aznar S.C. This transaction was closed on 15 December 2021, where MCRM advised Adium in Argentina, while Bergstein Abogados, Harney Westwood & Riegels LP, Caraza y Morayta Abogados and Reyes & Reyes Abogados acted as advisors to Adium in Uruguay, the British Virgin Islands, Mexico and Colombia respectively. The loan proceeds will be used to finance Adium’s acquisition of certain pharmaceutical products from Takeda Pharmaceutical International AG in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama and other Caribbean countries. as borrower, in a loan agreement up to a maximum principal amount of $130,000,000 US dollars by Banco Itaú Uruguay S.A., as sole lead arranger and bookrunner, together with other financial institutions and banks, as lenders and TMF Group New York LLC, as administrative agent.Īdium’s parent company and certain subsidiaries of the borrower have provided corporate guarantees. Mitrani, Caballero & Ruiz Moreno Abogados has advised Adium Pharma S.A. Mitrani, Caballero & Ruiz Moreno has represented Adium Pharma as borrower in the 130 million loan granted by Banco Itaú ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |